Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM-1021 in Advanced Malignancies
NCT06823167Phase 1Recruiting
- Sponsor
- Immunome
- Start
- Feb 2025
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of im-1021 in solid tumor and B cell lymphoma (2 arms), sponsored by Immunome. Primary endpoints: Incidence of Treatment Emergent Adverse Events and Recommended dose(s) and schedule(s) of IM-1021. Started Feb 2025; status: recruiting.
02
Drugs
im-1021
03
Conditions
solid tumorB cell lymphoma
Beyond the preview
Go deeper on NCT06823167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823167.